These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28986242)

  • 1. An alternative approach identified optimal risk thresholds for treatment indication: an illustration in coronary heart disease.
    van Giessen A; de Wit GA; Moons KGM; Dorresteijn JAN; Koffijberg H
    J Clin Epidemiol; 2018 Feb; 94():122-131. PubMed ID: 28986242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
    Heller DJ; Coxson PG; Penko J; Pletcher MJ; Goldman L; Odden MC; Kazi DS; Bibbins-Domingo K
    Circulation; 2017 Sep; 136(12):1087-1098. PubMed ID: 28687710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
    Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
    Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of statins in coronary heart disease.
    Franco OH; Peeters A; Looman CW; Bonneux L
    J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK.
    Scuffham PA; Chaplin S
    Pharmacoeconomics; 2004; 22(8):525-35. PubMed ID: 15217308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.
    Stam-Slob MC; van der Graaf Y; Greving JP; Dorresteijn JA; Visseren FL
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA).
    Roberts ET; Horne A; Martin SS; Blaha MJ; Blankstein R; Budoff MJ; Sibley C; Polak JF; Frick KD; Blumenthal RS; Nasir K
    PLoS One; 2015; 10(3):e0116377. PubMed ID: 25786208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
    Davies GM; Vyas A; Baxter CA
    J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.
    Aarnio E; Korhonen MJ; Huupponen R; Martikainen J
    Atherosclerosis; 2015 Mar; 239(1):240-7. PubMed ID: 25618032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
    Jacobson TA
    Curr Opin Lipidol; 1997 Dec; 8(6):369-74. PubMed ID: 9412778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA; Simoons ML
    Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
    Pignone M; Earnshaw S; Tice JA; Pletcher MJ
    Ann Intern Med; 2006 Mar; 144(5):326-36. PubMed ID: 16520473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis.
    Hong JC; Blankstein R; Shaw LJ; Padula WV; Arrieta A; Fialkow JA; Blumenthal RS; Blaha MJ; Krumholz HM; Nasir K
    JACC Cardiovasc Imaging; 2017 Aug; 10(8):938-952. PubMed ID: 28797417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
    Roze S; Ferrières J; Bruckert E; Van Ganse E; Chapman MJ; Liens D; Renaudin C
    Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.